Clinical trial
MCLENA-2: A Phase II Clinical Trial for the Assessment of Biomarker Trajectory in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Treated With Lenalidomide (Amendment to IND # 142121)
NCT06177028 is registered in ClinicalTrials.gov with St. Joseph's Hospital and Medical Center, Phoenix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MCLENA-2: A Phase II Clinical Trial for the Assessment of Biomarker Trajectory in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Treated With Lenalidomide (Amendment to IND # 142121)
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 1, 2025
- Completion date
- January 2, 2027
- Enrollment
- 45 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
amyloid plaque, cognitive dysfunction, cognitive impairment, mild, inflammation, brain, neurodegenerative disease, hereditary